Page 4 - Ralph Tripp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Newly Developed RSV Vaccine Offers Immunity While Lowering the Risk of Dangerous Pulmonary Inflammation

/PRNewswire/ Scientists at Artificial Cell Technologies (ACT) have developed a fully synthetic microparticle vaccine for Respiratory Syncytial Virus (RSV).

New havenUnited statesRalph trippJeff powellArtificial cell technologies incArtificial cell tech incNational institutes of allergyUniversity of georgia college veterinary medicineArtificial cell technologiesRespiratory syncytial virusVice presidentGeorgia collegeVeterinary medicineNational institutesInfectious diseasesCell technologies

TrippBio Announces Close of Enrollment in the Phase 2 Study of PanCytoVir™ in Patients with Mild-to-Moderate COVID-19

TrippBio, Inc. (TrippBio), a clinical development-stage biopharmaceutical company developing antiviral treatments announces that the last patient was enrolled

University of georgiaUnited statesDavide martinRalph trippTrippbio incUniversity of georgia research foundationGeorgia research allianceInhibits respiratory syncytial virusGeorgia research alliance chairGeorgia research foundationMild to moderateCovid 19

TrippBio and University of Georgia Research Foundation Announce Filing of Additional Patent Application

TrippBio and University of Georgia Research Foundation Announce Filing of Additional Patent Application
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.

University of georgiaUnited statesDavide martinRalph trippAugusta universityCollege of public healthTrippbio incUniversity of georgia research foundationNavy supply corps schoolGeorgia research allianceGeorgia research foundationPreventing viralPatent cooperation treatyChief scientific officerInhibits respiratory syncytial virusGeorgia research alliance chair

TrippBio and University of Georgia Research Foundation Expand Licensing Agreement for PanCytoVir™ and Analogs

The revised agreement broadens TrippBio’s pipeline with new chemical entities that show promise as broadly active anti-viral treatments

University of georgiaUnited statesDavide martinRalph trippAugusta universityCollege of public healthTrippbio incUniversity of georgia research foundationNavy supply corps schoolGeorgia research allianceGeorgia research foundationLicensing agreementInhibits respiratory syncytial virusGeorgia research alliance chairPublic health

TrippBio Announces Initiation of the Phase 2 Study to Evaluate PanCytoVir™ in Patients with Mild-to-Moderate COVID-19

First patient screened in study to define the antiviral effect of PanCytoVir™ in patients with mild-to-moderate COVID-19

University of georgiaUnited statesDavide martinRalph trippTrippbio incUniversity of georgia research foundationGeorgia research allianceGeorgia research alliance chairGeorgia research foundationInhibits respiratory syncytial virus